OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001349929

Vyant Bio, Inc.

Vyant Bio, Inc. (CIK 0001349929, EIN 04-3462475) reported revenue of $666,000 for FY2022 (2022-01-01 to 2022-12-31) and net income of -$22.69 million (-$22,690,000) for FY2022 (2022-01-01 to 2022-12-31), as filed in its 10-K filed 2023-03-31 (accession 0001493152-23-010255).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001349929
EIN04-3462475
SIC industry code8071 Services-Medical Laboratories
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_0z4152b46mdk45ne3xy1q9grmz
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$666,000FY20222022-01-01 to 2022-12-3110-K2023-03-310001493152-23-010255RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$22,690,000FY20222022-01-01 to 2022-12-3110-K2023-03-310001493152-23-010255NetIncomeLoss
Total assets$15,205,000FY2022as of 2022-12-3110-K2023-03-310001493152-23-010255Assets
Total liabilities$5,296,000FY2022as of 2022-12-3110-K2023-03-310001493152-23-010255Liabilities
Stockholders' equity$9,909,000FY2022as of 2022-12-3110-K2023-03-310001493152-23-010255StockholdersEquity
Operating cash flow-$13,681,000FY20222022-01-01 to 2022-12-3110-K2023-03-310001493152-23-010255NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$1.81 per shareFY20212021-01-01 to 2021-12-3110-K2022-03-300001493152-22-008085EarningsPerShareBasicAndDiluted
Shares outstanding6,267,708 sharesFY2022as of 2023-03-1510-K2023-03-310001493152-23-010255EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2013-2022, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20222022-01-01 to 2022-12-31$666,00010-K2023-03-310001493152-23-010255
RevenueFY20212021-01-01 to 2021-12-31$1,148,00010-K2023-03-310001493152-23-010255
RevenueFY20202020-01-01 to 2020-12-31$867,00010-K2022-03-300001493152-22-008085
RevenueFY20192019-01-01 to 2019-12-31$7,305,00010-K2021-03-310001349929-21-000004
RevenueFY20182018-01-01 to 2018-12-31$4,932,00010-K2020-05-290001349929-20-000005
RevenueFY20172017-01-01 to 2017-12-31$29,121,00010-K2018-04-020001349929-18-000002
RevenueFY20162016-01-01 to 2016-12-31$27,049,00010-K2018-04-020001349929-18-000002
RevenueFY20152015-01-01 to 2015-12-31$18,040,00010-K2017-03-230001349929-17-000024
RevenueFY20142014-01-01 to 2014-12-31$10,199,00010-K2016-03-100001349929-16-000062
RevenueFY20132013-01-01 to 2013-12-31$6,610,00010-K2016-03-100001349929-16-000062
Net incomeFY20222022-01-01 to 2022-12-31-$22,690,00010-K2023-03-310001493152-23-010255
Net incomeFY20212021-01-01 to 2021-12-31-$40,859,00010-K2023-03-310001493152-23-010255
Net incomeFY20202020-01-01 to 2020-12-31-$8,650,00010-K2022-03-300001493152-22-008085
Net incomeFY20192019-01-01 to 2019-12-31-$6,708,00010-K2021-03-310001349929-21-000004
Net incomeFY20182018-01-01 to 2018-12-31-$20,373,00010-K2020-05-290001349929-20-000005
Net incomeFY20172017-01-01 to 2017-12-31-$20,880,00010-K2019-04-160001349929-19-000003
Net incomeFY20162016-01-01 to 2016-12-31-$15,803,00010-K2018-04-020001349929-18-000002
Net incomeFY20152015-01-01 to 2015-12-31-$20,184,00010-K2017-03-230001349929-17-000024
Net incomeFY20142014-01-01 to 2014-12-31-$16,643,00010-K2016-03-100001349929-16-000062
Net incomeFY20132013-01-01 to 2013-12-31-$12,373,00010-K2016-03-100001349929-16-000062
  • Revenue for FY2020 was restated: first reported as $5,751,000 (accession 0001349929-21-000004, filed 2021-03-31).
  • Revenue for FY2018 was restated: first reported as $27,470,000 (accession 0001349929-19-000003, filed 2019-04-16).
  • Revenue for FY2014 was restated: first reported as $10,199,387 (accession 0001349929-15-000004, filed 2015-03-16).
  • Revenue for FY2013 was restated: first reported as $6,609,957 (accession 0001193125-14-121698, filed 2014-03-28).
  • Net income for FY2020 was restated: first reported as -$8,001,000 (accession 0001349929-21-000004, filed 2021-03-31).
  • Net income for FY2014 was restated: first reported as -$16,642,919 (accession 0001349929-15-000004, filed 2015-03-16).
  • Net income for FY2013 was restated: first reported as -$12,372,553 (accession 0001193125-14-121698, filed 2014-03-28).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-K2023-03-312022-12-310001493152-23-010255form10-k.htm
10-Q2022-11-142022-09-300001493152-22-032074form10-q.htm
10-Q2022-08-222022-06-300001493152-22-023727form10-q.htm
10-Q2022-05-162022-03-310001493152-22-013854form10-q.htm
10-K2022-03-302021-12-310001493152-22-008085form10-k.htm
10-Q2021-11-122021-09-300001493152-21-028038form10-q.htm
10-Q2021-08-162021-06-300001493152-21-020254form10-q.htm
10-Q2021-05-172021-03-310001493152-21-011952form10q.htm
10-K2021-03-312020-12-310001349929-21-000004cgix-20201231.htm
10-Q2020-11-122020-09-300001349929-20-000017cgix-20200930.htm
10-Q2020-08-132020-06-300001349929-20-000013cgix-20200630.htm
10-Q/A2020-07-062020-03-310001493152-20-012592form10-qa.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001349929published by the sourcedata.sec.gov/submissions/CIK0001349929.json2026-10-21
Employer Identification Number (EIN) · US-EIN04-3462475published by the sourcedata.sec.gov/submissions/CIK0001349929.json2026-10-21

Former names

NameFromTo
CANCER GENETICS, INC2011-12-302021-03-31
CANCER GENETICS INC2006-01-102010-11-01

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001349929.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001349929.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001349929" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001349929/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001349929/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1349929"}

On SEC EDGAR

About this data